EditorialEditorial

Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

Hongquan Wang, Shuang Wu, Yan Wang and Bo Tang
Cancer Biology & Medicine July 2022, 19 (7) 945-947; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0299

References

  1. 1.↵
    2. Lambert A,
    3. Conroy T,
    4. Ducreux M.
    Future directions in drug development in pancreatic cancer. Semin Oncol. 2021; 48: 47–56.
    OpenUrl
  2. 2.↵
    2. Easwaran H,
    3. Tsai HC,
    4. Baylin SB.
    Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014; 54: 716–27.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Lodestijn SC,
    3. van Neerven SM,
    4. Vermeulen L,
    5. Bijlsma MF.
    Stem cells in the exocrine pancreas during homeostasis, injury, and cancer. Cancers (Basel). 2021; 13: 3295.
    OpenUrl
  4. 4.↵
    2. Bayik D,
    3. Lathia JD.
    Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021; 21: 526–36.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Oshimori N,
    3. Guo Y,
    4. Taniguchi S.
    An emerging role for cellular crosstalk in the cancer stem cell niche. J Pathol. 2021; 254: 384–94.
    OpenUrl
  6. 6.↵
    2. Chan TS,
    3. Shaked Y,
    4. Tsai KK.
    Targeting the interplay between cancer fibroblasts, mesenchymal stem cells, and cancer stem cells in desmoplastic cancers. Front Oncol. 2019; 9: 688.
    OpenUrlPubMed
  7. 7.↵
    2. Sagara A,
    3. Nakata K,
    4. Yamashita T,
    5. Guan W,
    6. Zhong P,
    7. Matsumoto S, et al.
    New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Pancreatology. 2021 S1424-3903(21)00141-1: Online ahead of print doi:10.1016/j.pan.2021.04.002.
    OpenUrlCrossRef
  8. 8.
    2. Dalin S,
    3. Sullivan MR,
    4. Lau AN,
    5. Grauman-Boss B,
    6. Mueller HS,
    7. Kreidl E, et al.
    Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 2019; 79: 5723–33.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Wu Y,
    3. Zhang C,
    4. Jiang K,
    5. Werner J,
    6. Bazhin AV,
    7. D’Haese JG.
    The role of stellate cells in pancreatic ductal adenocarcinoma: targeting perspectives. Front Oncol. 2020; 10: 621937.
  10. 10.↵
    2. Chen X,
    3. Zhang Y,
    4. Qian W,
    5. Han L,
    6. Li W,
    7. Duan W, et al.
    Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. iScience. 2021; 24: 103400.
  11. 11.↵
    2. Zhou T,
    3. Liu J,
    4. Xie Y,
    5. Yuan S,
    6. Guo Y,
    7. Bai W, et al.
    ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Gut. 2022; 71: 357–71.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Jha NN,
    3. Kumar R,
    4. Panigrahi R,
    5. Navalkar A,
    6. Ghosh D,
    7. Sahay S, et al.
    Comparison of α-Synuclein fibril inhibition by four different amyloid inhibitors. ACS Chem Neurosci. 2017; 8: 2722–33.
    OpenUrl
  13. 13.↵
    2. Albino D,
    3. Longoni N,
    4. Curti L,
    5. Mello-Grand M,
    6. Pinton S,
    7. Civenni G, et al.
    ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res. 2012; 72: 2889–900.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Li J,
    3. Yang J,
    4. Hua L,
    5. Wang R,
    6. Li H,
    7. Zhang C, et al.
    Ese-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B. Am J Cancer Res. 2021; 11: 92–107.
    OpenUrl
  15. 15.↵
    2. Lyu Z,
    3. Ma M,
    4. Xu Y,
    5. Wang X,
    6. Zhu Y,
    7. Ren W, et al.
    Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. Int J Clin Oncol. 2020; 25: 1334–45.
    OpenUrl
  16. 16.↵
    2. Zhao T,
    3. Jiang W,
    4. Wang X,
    5. Wang H,
    6. Zheng C,
    7. Li Y, et al.
    ESE3 Inhibits pancreatic cancer metastasis by upregulating E-cadherin. Cancer Res. 2017; 77: 874–85.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Liu J,
    3. Jiang W,
    4. Zhao K,
    5. Wang H,
    6. Zhou T,
    7. Bai W, et al.
    Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. J Exp Med. 2019; 216: 656–73.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section